Current Opinion in Gastroenterology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 3, 2025
Purpose of review Metabolic dysfunction-associated steatotic liver disease (MASLD) is present in 25–35% individuals the United States. The purpose this to provide contextual framework for hepatic ketogenesis MASLD and spotlight recent advances that have improved our understanding mechanisms drive its development progression. Recent findings Traditionally, has only been considered metabolically during prolonged fasting/starvation or with carbohydrate deplete ketogenic diets where ketones important alternative energy sources. Over past 2 years, it become increasingly clear from preclinical rodent human clinical studies insufficiency a key contributor initiation progression MASLD. Summary A more thorough metabolic dysregulation occurs between extrahepatic tissues significant potential innovative nutritional pharmacological approaches treatment
Language: Английский